MX2019005397A - Proteinas de union a antigeno que antagonizan el receptor de leptina. - Google Patents

Proteinas de union a antigeno que antagonizan el receptor de leptina.

Info

Publication number
MX2019005397A
MX2019005397A MX2019005397A MX2019005397A MX2019005397A MX 2019005397 A MX2019005397 A MX 2019005397A MX 2019005397 A MX2019005397 A MX 2019005397A MX 2019005397 A MX2019005397 A MX 2019005397A MX 2019005397 A MX2019005397 A MX 2019005397A
Authority
MX
Mexico
Prior art keywords
antibodies
antigen
binding fragments
lepr
bind
Prior art date
Application number
MX2019005397A
Other languages
English (en)
Inventor
Stevis Panayiotis
Altarejos Judith
Gromada Jesper
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2019005397A publication Critical patent/MX2019005397A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona anticuerpos y fragmentos de unión a antígeno de anticuerpos que se unen al receptor de leptina (LEPR), y métodos para usarlos. De acuerdo con ciertas realizaciones, la invención incluye anticuerpos y fragmentos de unión a antígeno de anticuerpos que se unen a LEPR y antagonizan la señalización de LEPR. En ciertas realizaciones, la invención incluye anticuerpos y fragmentos de unión a antígeno de anticuerpos que se unen a LEPR en presencia o ausencia de leptina. En otras realizaciones, la invención incluye anticuerpos y fragmentos de unión a antígeno de anticuerpos que exhiben agonismo parcial de señalización LEPR. Los anticuerpos y fragmentos de unión a antígeno de la presente invención son útiles para el tratamiento de diversas afecciones, que incluyen, pero no se limitan a, caquexia por insuficiencia cardíaca congestiva, caquexia pulmonar y caquexia por cáncer, trastornos autoinmunes como enfermedad inflamatoria intestinal, lupus eritematoso, esclerosis múltiple, psoriasis, enfermedades cardiovasculares, presión arterial elevada, trastornos neurodegenerativos, depresión, cáncer como carcinoma hepatocelular, melanoma, cáncer de mama, y otras enfermedades y trastornos asociados con o causados por una elevada señalización de leptina.
MX2019005397A 2016-11-08 2017-11-08 Proteinas de union a antigeno que antagonizan el receptor de leptina. MX2019005397A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662419062P 2016-11-08 2016-11-08
PCT/US2017/060690 WO2018089532A1 (en) 2016-11-08 2017-11-08 Antigen-binding proteins that antagonize leptin receptor

Publications (1)

Publication Number Publication Date
MX2019005397A true MX2019005397A (es) 2019-10-09

Family

ID=60409473

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019005397A MX2019005397A (es) 2016-11-08 2017-11-08 Proteinas de union a antigeno que antagonizan el receptor de leptina.
MX2023011233A MX2023011233A (es) 2016-11-08 2019-05-08 Proteinas de union a antigeno que antagonizan el receptor de leptina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023011233A MX2023011233A (es) 2016-11-08 2019-05-08 Proteinas de union a antigeno que antagonizan el receptor de leptina.

Country Status (18)

Country Link
US (3) US10550192B2 (es)
EP (1) EP3538554A1 (es)
JP (4) JP7042816B2 (es)
KR (1) KR102563568B1 (es)
CN (1) CN110167965A (es)
AU (1) AU2017359439A1 (es)
CA (1) CA3043365A1 (es)
CL (3) CL2019001263A1 (es)
CO (1) CO2019004672A2 (es)
EA (1) EA201991075A1 (es)
IL (2) IL266426B (es)
MA (1) MA45801B1 (es)
MX (2) MX2019005397A (es)
MY (1) MY191256A (es)
PH (1) PH12019500988A1 (es)
SG (1) SG10201913470SA (es)
UA (1) UA127678C2 (es)
WO (1) WO2018089532A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110167965A (zh) 2016-11-08 2019-08-23 瑞泽恩制药公司 拮抗瘦素受体的抗原结合蛋白
US11834500B2 (en) 2017-12-18 2023-12-05 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereof
KR20200141461A (ko) 2018-04-06 2020-12-18 리제너론 파마슈티칼스 인코포레이티드 렙틴 수용체 작용제 항체를 사용한 치료 방법
WO2020016160A1 (en) * 2018-07-16 2020-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat neurological diseases
CN113195532A (zh) * 2018-12-18 2021-07-30 瑞泽恩制药公司 使用针对瘦素受体、gdf8和活化素a的拮抗剂增加体重和瘦肌肉质量的组合物和方法
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
AU2021343444A1 (en) * 2020-09-15 2023-04-20 Regeneron Pharmaceuticals, Inc. Use of lepr agonists for pain
CN118436632B (zh) * 2024-07-05 2024-08-30 四川大学华西第二医院 Teriflunomide在制备预防和/或治疗原发性纤毛不动综合征的药物中的用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643748A (en) 1994-09-14 1997-07-01 Progenitor, Inc. HU-B1.219, a novel human hematopoietin receptor
US5856098A (en) 1994-09-14 1999-01-05 Progenitor, Inc. Detection of a leptin receptor variant
US5912123A (en) 1994-09-14 1999-06-15 Progenitor, Inc. Detection of the leptin receptor in reproductive organs and methods for regulating reproductive biology
US6451523B1 (en) 1994-09-14 2002-09-17 Interneuron Pharmaceuticals, Inc. Detection of a leptin receptor variant and methods for regulating obesity
US6482927B1 (en) 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
US6977240B1 (en) 1995-11-27 2005-12-20 Millenium Pharmaceuticals, Inc. Methods of using the OB receptor antibodies to treat bodyweight disorders
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
IL125073A0 (en) 1996-01-08 1999-01-26 Genentech Inc Wsx receptor and ligands
AU2476301A (en) 1996-01-16 2001-05-24 Rockefeller University, The DB the receptor for leptin nucleic acids encoding the receptor, and uses thereof
US7063958B1 (en) 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
AU1833197A (en) 1996-01-18 1997-08-11 Progenitor, Inc. Detection of a leptin receptor variant and methods for regulating obesity
EP1731164A1 (en) 1996-01-23 2006-12-13 Indevus Pharmaceuticals, Inc. Methods for using the obese gene and its gene product to stimulate hematopoietic development
US7067472B1 (en) 1996-06-04 2006-06-27 The Scripps Research Institute Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies
US5965521A (en) 1997-02-25 1999-10-12 Eli Lilly Company Pulsatile delivery of leptin receptor ligands
IL120733A0 (en) 1997-04-29 1997-08-14 Yeda Res & Dev Leptin as an inhibitor of cell proliferation
US6696411B1 (en) 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
AU767068B2 (en) 1999-06-11 2003-10-30 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of leptin activity
US20040253242A1 (en) 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
FR2852397B1 (fr) 2003-03-10 2005-04-29 Utilisation des genes leprotl 1 et ob-rgrp pour le criblage de composes actifs sur la prise ou la perte de poids ou le diabete d'un sujet humain ou animal.
ES2289235T3 (es) * 2003-08-21 2008-02-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Nuevo antagonista de leptina.
DE10353593A1 (de) * 2003-11-17 2005-06-23 Klinikum der Universität München Großhadern-Innenstadt Leptinantagonist und Verfahren zur quantitativen Messung von Leptin
US7863240B2 (en) 2004-10-08 2011-01-04 Enzo Therapeutics, Inc. Methods and uses of leptin in hepatocellular carcinoma
US8969291B2 (en) 2004-10-08 2015-03-03 Enzo Therapeutics, Inc. Methods for decreasing leptin levels or activity for treating inflammation
CA2585549A1 (en) 2004-11-18 2006-05-26 Vib Vzw Novel type leptin receptor antagonist
US7307142B2 (en) * 2004-11-26 2007-12-11 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Leptin antagonists
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
GB0715216D0 (en) 2007-08-03 2007-09-12 Asterion Ltd Leptin
EP2356270B1 (en) 2008-11-07 2016-08-24 Fabrus Llc Combinatorial antibody libraries and uses thereof
KR101398363B1 (ko) 2010-11-17 2014-05-22 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
CN103476433A (zh) 2011-02-10 2013-12-25 罗切格利卡特公司 改良的免疫疗法
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
PT2895513T (pt) 2012-09-12 2018-10-08 Genzyme Corp Polipéptidos contendo fc com glicosilação alterada e função efetora reduzida
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
JP6666848B2 (ja) 2014-02-18 2020-03-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｎｒｐ−１／ｏｂｒ複合体シグナル伝達経路により媒介される疾患の処置のための方法及び医薬組成物
TWI824372B (zh) 2015-10-12 2023-12-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
CN110167965A (zh) 2016-11-08 2019-08-23 瑞泽恩制药公司 拮抗瘦素受体的抗原结合蛋白

Also Published As

Publication number Publication date
UA127678C2 (uk) 2023-11-29
WO2018089532A1 (en) 2018-05-17
CN110167965A (zh) 2019-08-23
IL272358A (en) 2020-03-31
KR102563568B1 (ko) 2023-08-04
US11535675B2 (en) 2022-12-27
US10550192B2 (en) 2020-02-04
AU2017359439A1 (en) 2019-05-23
CL2020000549A1 (es) 2020-08-28
JP7042816B2 (ja) 2022-03-28
US20200123264A1 (en) 2020-04-23
SG10201913470SA (en) 2020-03-30
MA45801A1 (fr) 2020-07-29
JP2020504078A (ja) 2020-02-06
US20180127508A1 (en) 2018-05-10
CA3043365A1 (en) 2018-05-17
MA45801B1 (fr) 2021-11-30
JP2024109952A (ja) 2024-08-14
PH12019500988A1 (en) 2019-08-19
EP3538554A1 (en) 2019-09-18
IL266426B (en) 2020-11-30
CO2019004672A2 (es) 2019-07-31
EA201991075A1 (ru) 2019-10-31
IL266426A (en) 2019-06-30
IL272358B (en) 2022-02-01
CL2019001263A1 (es) 2019-09-27
JP2023093753A (ja) 2023-07-04
MY191256A (en) 2022-06-10
CL2020001023A1 (es) 2020-10-09
US20230235068A1 (en) 2023-07-27
MX2023011233A (es) 2023-10-03
KR20190075133A (ko) 2019-06-28
JP2022031969A (ja) 2022-02-22

Similar Documents

Publication Publication Date Title
MX2023011233A (es) Proteinas de union a antigeno que antagonizan el receptor de leptina.
PH12019502283A1 (en) Anti-lag3 antibodies
ZA202000373B (en) Anti-cd47 antibodies and uses thereof
MX2018012757A (es) Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
PH12018500086A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
NZ738008A (en) Tigit-binding agents and uses thereof
MX2017001599A (es) Anticuerpos novedosos y sus usos.
PH12016501366A1 (en) Novel anti-baff antibodies
PH12021550690A1 (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
MX2023012740A (es) Anticuerpos antifactor de la coagulacion xi.
MA40527A (fr) Protéines de liaison à l'antigène se liant à wisp5
EA201890572A1 (ru) Биофармацевтические композиции
WO2012075342A3 (en) Anti-bradykinin b2 receptor (bkb2r) monoclonal antibody
PH12019502694A1 (en) Anti-trkb antibodies
PH12020551805A1 (en) Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof
MY190021A (en) Anti-gm-csf antibodies and uses thereof
PH12016501326A1 (en) (s)-3'-methyl-abscisic acid and esters thereof
EA201990493A1 (ru) Антитела к гм-ксф и их применения
MX2018007221A (es) Moleculas de anticuerpos que se unen al factor de necrosis tumoral alfa (tnf alfa).
WO2016179579A3 (en) Cytoplasmic and nuclear antibody compositions and methods of use thereof